Comparative Pharmacology
Head-to-head clinical analysis: CAPRELSA versus NILOTINIB D TARTRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPRELSA versus NILOTINIB D TARTRATE.
CAPRELSA vs NILOTINIB D-TARTRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and oncogenesis, including VEGFR2, EGFR, and RET.
BCR-ABL tyrosine kinase inhibitor; binds to and inhibits the ATP-binding site of BCR-ABL, thereby inhibiting tyrosine kinase activity and downstream signaling pathways, leading to apoptosis in CML cells.
300 mg orally once daily, with or without food.
400 mg orally twice daily, approximately 12 hours apart, with food.
None Documented
None Documented
Terminal half-life approximately 90 hours (range 30–150 hours), supporting once-daily dosing; steady-state achieved by day 15.
17 hours (terminal elimination half-life); supports once-daily dosing
Primarily fecal (approximately 75% of administered dose, mainly as unchanged drug and metabolites); renal excretion accounts for about 25% (less than 1% unchanged).
Fecal (93%), renal (4%)
Category C
Category D/X
Kinase Inhibitor
Kinase Inhibitor